A guide to cancer immunotherapy: from T cell basic science to clinical practice

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis

Tang, X., Gao, L., Jiang, X., Hou, Z., Wang, Y., Hou, S., & Qu, H. (2024) · Oncogene · doi:10.1038/s41388-024-03114-0 · Cited by 36

Role of NEK2 in tumorigenesis and tumor progression

Xia, J., Zhao, H., Edmondson, J. L., Koss, B. S., & Zhan, F. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.013 · Cited by 37

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies

Wu, J., Bloch, N., Chang, A. Y., Bhavsar, R., Wang, Q., Crawford, A., DiLillo, D. J., Vazzana, K., Mohrs, K., Dudgeon, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101747 · Cited by 36

Current advancements in cellular immunotherapy for autoimmune disease

Berry, C. T., Frazee, C. P., Herman, P. J., Chen, S., Chen, A., Kuo, Y., & Ellebrecht, C. T. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-024-01034-5 · Cited by 38

Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond

Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 37

The Role of TNF-α in Neuropathic Pain: An Immunotherapeutic Perspective

García‐Domínguez, M. (2025) · Life · doi:10.3390/life15050785 · Cited by 40

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

Kast, F., Klein, C., Umaña, P., Gros, A., & Gasser, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1869389 · Cited by 34

Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer

Sissy, C. E., Kirilovsky, A., Zeitoun, G., Marliot, F., Haicheur, N., Lagorce, C., Galon, J., & Pagès, F. (2021) · Cancers · doi:10.3390/cancers13061281 · Cited by 34

The systemic immune-inflammation index-based model is an effective biomarker on predicting central lymph node metastasis in clinically nodal-negative papillary thyroid carcinoma

Zhang, Z., Xia, F., Wang, W., Huang, Y., & Li, X. (2021) · Gland Surgery · doi:10.21037/gs-20-666 · Cited by 34

Cholangiocarcinoma: new perspectives for new horizons

Rimini, M., Puzzoni, M., Pedica, F., Silvestris, N., Fornaro, L., Aprile, G., Loi, E., Brunetti, O., Vivaldi, C., Simionato, F., et al. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991313 · Cited by 36

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Tarantelli, C., Argnani, L., Zinzani, P. L., & Bertoni, F. (2021) · Cancers · doi:10.3390/cancers13215535 · Cited by 35

Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks

Fobian, S., Cheng, Z., & ten Hagen, T. L. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010026 · Cited by 35

Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells

Han, B., Song, Y., Park, J., & Doh, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.049 · Cited by 33

Tissue-Resident Memory CD4+ T Cells Play a Dominant Role in the Initiation of Antitumor Immunity

Zhang, H., Zhu, Z., Modrak, S., & Little, A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100852 · Cited by 34

Methionine cycle-dependent regulation of T cells in cancer immunity

Zhao, T., & Lum, J. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969563 · Cited by 34

Self‐Splittable Transcytosis Nanoraspberry for NIR‐II Photo‐Immunometabolic Cancer Therapy in Deep Tumor Tissue

Wang, L., Jiang, W., Su, Y., Zhan, M., Peng, S., Liu, H., & Lu, L. (2022) · Advanced Science · doi:10.1002/advs.202204067 · Cited by 34

The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer

Bizzarri, N., D’Indinosante, M., Marchetti, C., Tudisco, R., Turchiano, F., Scambia, G., & Fagotti, A. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02272-z · Cited by 34

Recent progress in cancer immunotherapy: Overview of current status and challenges

Darvishi, M., Tosan, F., Nakhaei, P., Manjili, D. A., Kharkouei, S. A., Alizadeh, A. M., Ilkhani, S., Khalafi, F., Zadeh, F. A., & Shafagh, S.-G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154241 · Cited by 35

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

Callari, M., Sola, M., Magrin, C., Rinaldi, A., Bolis, M., Paganetti, P., Colnaghi, L., & Papin, S. (2023) · Scientific Data · doi:10.1038/s41597-023-02543-y · Cited by 36

Near-Infrared Light-Boosted Photodynamic-Immunotherapy based on sulfonated Metal-Organic framework nanospindle

Li, Y., Zhou, J., Chen, Y., Pei, Q., Li, Y., Wang, L., & Xie, Z. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135370 · Cited by 33

Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer

Zhao, Y., Liu, Y., Jia, Y., Wang, X., He, J., Zhen, S., Wang, J., & Liu, L. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04250-4 · Cited by 34

Black Phosphorus-Synergic Nitric Oxide Nanogasholder Spatiotemporally Regulates Tumor Microenvironments for Self-Amplifying Immunotherapy

Huang, X., Zhong, Y., Li, Y., Zhou, X. Y., Yang, L., Zhao, B., Zhou, J., Qiao, H., Huang, D., Qian, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10098 · Cited by 33

Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes

Clubb, J. D., Gao, T. A., & Chen, Y. Y. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1491 · Cited by 35

Radio-induced lymphopenia in the era of anti-cancer immunotherapy

de Kermenguy, F., Meziani, L., Mondini, M., Clémenson, C., Morel, D., Deutsch, É., & Robert, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.002 · Cited by 34

Overcoming the challenges of infrared photosensitizers in photodynamic therapy: the making of redaporfin

Arnaut, L. G., & Pereira, M. M. (2023) · Chemical Communications · doi:10.1039/d3cc02283h · Cited by 37

Cracking the Codes behind Cancer Cells’ Immune Evasion

Mundhara, N., & Sadhukhan, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168899 · Cited by 37

Design of high-affinity binders to immune modulating receptors for cancer immunotherapy

Yang, W., Hicks, D. R., Ghosh, A., Schwartze, T. A., Conventry, B., Goreshnik, I., Allen, A., Halabiya, S. F., Kim, C. J., Hinck, C. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57192-z · Cited by 40

Imaging 3D cell cultures with optical microscopy

Hsieh, H.-C., Han, Q., Brenes, D., Bishop, K. W., Wang, R., Wang, Y., Poudel, C., Glaser, A. K., Freedman, B., Vaughan, J. C., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02647-w · Cited by 38

Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy

von Locquenghien, M., Zwicky, P., Xie, K., Jaitin, D. A., Sheban, F., Yalin, A., Uhlitz, F., Gur, C., Sharet-Eshed, R., David, E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.030 · Cited by 41

Overcoming biological barriers to improve solid tumor immunotherapy

Ukidve, A., Cu, K., Kumbhojkar, N., Lahann, J., & Mitragotri, S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00923-8 · Cited by 33

Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children

Torun, A., Hupalowska, A., Trzonkowski, P., Kierkuś, J., & Pyrzyńska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642166 · Cited by 40

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 33

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances

Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., & Nakatsura, T. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291558 · Cited by 35

Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials

Schmidt, M. W., Battista, M. J., Schmidt, M., Garcia, M., Siepmann, T., Hasenburg, A., & Anić, K. (2022) · Cancers · doi:10.3390/cancers14020441 · Cited by 37

RAS pathway regulation in melanoma

Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 33

Fat mass and obesity‐associated protein regulates arecoline‐exposed oral cancer immune response through programmed cell death‐ligand 1

Li, X., Chen, W., Gao, Y., Song, J., Gu, Y., Zhang, J., Cheng, X., & Ai, Y. (2022) · Cancer Science · doi:10.1111/cas.15332 · Cited by 32

HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Liu, K., Huang, J., Liu, J., Li, C., Kroemer, G., Tang, D., & Kang, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3917 · Cited by 33

NLRP1 Inflammasome Activation in Keratinocytes: Increasing Evidence of Important Roles in Inflammatory Skin Diseases and Immunity

Fenini, G., Karakaya, T., Hennig, P., Filippo, M. D., Slaufova, M., & Beer, H. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.04.004 · Cited by 35

Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition

Daly, R. J., Scott, A. M., Klein, O., & Ernst, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01656-z · Cited by 35

Strategies for Heating Up Cold Tumors to Boost Immunotherapies

Zabransky, D. J., Yarchoan, M. M., & Jaffee, E. M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040258 · Cited by 34

Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine

Hong, J., Jung, M., Kim, C., Kang, M., Go, S., Sohn, H. S., Moon, S., Kwon, S., Song, S. Y., & Kim, B. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00951-z · Cited by 34

The Roles of Secreted Wnt Ligands in Cancer

Werner, J., Boonekamp, K. E., Zhan, T., & Boutros, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065349 · Cited by 37

A Biomimetic Nanogel System Restores Macrophage Phagocytosis for Magnetic Resonance Imaging‐Guided Synergistic Chemoimmunotherapy of Breast Cancer

Li, L., Gao, Y., Zhang, Y., Yang, R., Ouyang, Z., Guo, R., Yu, H., Shi, X., & Cao, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300967 · Cited by 33

The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment

Fathima, J. K., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00289-6 · Cited by 33

Biomimetic nanoparticles for tumor immunotherapy

Yu, H., Wu, M., Chen, S., Song, M., & Yue, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.989881 · Cited by 32

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

Huang, R. S. P., Carbone, D. P., Li, G., Schrock, A. B., Graf, R. P., Zhang, L., Murugesan, K., Ross, J. S., Tolba, K. A., Sands, J. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005801 · Cited by 37

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions

Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 37

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review

Zheng, H., Wang, G., Liu, M., & Cheng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168226 · Cited by 32

Bioprinted Multicomponent Hydrogel Co-culture Tumor-Immune Model for Assessing and Simulating Tumor-Infiltrated Lymphocyte Migration and Functional Activation

Flores-Torres, S., Dimitriou, N. M., Pardo, L. A., Kort-Mascort, J., Pal, S., Peza-Chavez, O., Kuasne, H., Bérubé, J., Bertos, N., Park, M., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c02995 · Cited by 32

Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors

Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 35

Extracellular Matrix Scaffold‐Assisted Tumor Vaccines Induce Tumor Regression and Long‐Term Immune Memory

Pal, S., Chaudhari, R., Baurceanu, I., Hill, B. J., Nagy, B. A., & Wolf, M. T. (2024) · Advanced Materials · doi:10.1002/adma.202309843 · Cited by 32

Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future

Yarahmadi, A., Zare, M. A., Aghayari, M., Afkhami, H., & Jafari, G. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01622-w · Cited by 32

CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy

Qu, J., Wu, B., Chen, L., Wen, Z., Fang, L., Zheng, J., Shen, Q., Heng, J., Zhou, J., & Zhou, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03046-3 · Cited by 34

Nanoparticle Targeting Strategies for Lipid and Polymer‐Based Gene Delivery to Immune Cells In Vivo

Jain, M., Yu, X., Schneck, J. P., & Green, J. J. (2024) · Small Science · doi:10.1002/smsc.202400248 · Cited by 35

Targeting amino acid-metabolizing enzymes for cancer immunotherapy

Grobben, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440269 · Cited by 35

Immunomodulation by endothelial cells: prospects for cancer therapy

Alnaqbi, H., Becker, L. M., Mousa, M., Alshamsi, F. Y., Azzam, S. K., Veseli, B. E., Hymel, L. A., Alhosani, K. M., Alhusain, M., Mazzone, M., et al. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.002 · Cited by 38

Reinventing type 2 immunity in cancer

Wagner, M., Nishikawa, H., & Koyasu, S. (2025) · Nature · doi:10.1038/s41586-024-08194-2 · Cited by 36

Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy

Wang, H., Zhan, H., Pan, B., Zeng, L., Chen, Z., Liu, S., Zhang, Q., Hong, X., Lu, J., Lin, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501565 · Cited by 33

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy

Lu, Z.-D., Chen, Y., Shen, S., Xu, C., & Wang, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08329 · Cited by 33

CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model

Furusawa, A., Okada, R., Inagaki, F., Wakiyama, H., Kato, T., Furumoto, H., Fukushima, H., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2019922 · Cited by 32

Challenges of CRISPR-Based Gene Editing in Primary T Cells

Rezalotfi, A., Fritz, L. V., Förster, R., & Bošnjak, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031689 · Cited by 33

Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy

Deng, K., Yang, D., & Zhou, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071344 · Cited by 32

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors

Rahmy, S., Mishra, S. J., Murphy, S. P., Blagg, B. S. J., & Lü, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005045 · Cited by 32

Novel insights into Hodgkin lymphoma biology by single-cell analysis

Aoki, T., & Steidl, C. (2022) · Blood · doi:10.1182/blood.2022017147 · Cited by 32

Membrane-tethered activation design of a photosensitizer boosts systemic antitumor immunity via pyroptosis

Lu, P., Liu, X., Chu, X., Wang, F., & Jiang, J. (2023) · Chemical Science · doi:10.1039/d2sc07044h · Cited by 32

Translation of nutrigenomic research for personalised and precision nutrition for cancer prevention and for cancer survivors

Malcomson, F. C., & Mathers, J. C. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102710 · Cited by 36

Immunotherapy in Glioblastoma: A Clinical Perspective

Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31

Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma

Zhu, C., Jiang, L., Yao, M., & Fang, C. (2021) · BMC Oral Health · doi:10.1186/s12903-021-01813-8 · Cited by 31

LDHA: The Obstacle to T cell responses against tumor

Tang, Y., Gu, S., Zhu, L., Wu, Y., Zhang, W., & Zhao, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1036477 · Cited by 34

Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions

Visalakshan, R. M., Lowrey, M. K., Sousa, M. G. C., Helms, H. R., Samiea, A., Schutt, C. E., Moreau, J. M., & Bertassoni, L. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162905 · Cited by 32

Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1

Rudjord-Levann, A. M., Ye, Z., Hafkenscheid, L., Horn, S., Wiegertjes, R., Nielsen, M. I., Song, M., Mathiesen, C. B. K., Stoop, J., Stowell, S. R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106984 · Cited by 32

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy

Wong, C. W., Huang, Y., & Hurlstone, A. F. L. (2023) · Essays in Biochemistry · doi:10.1042/ebc20230001 · Cited by 33

Hypoxia-Induced Signaling in Gut and Liver Pathobiology

Solanki, S. A., & Shah, Y. M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-094743 · Cited by 34

The Curie temperature: a key playmaker in self-regulated temperature hyperthermia

Niraula, G., Wu, C., Yu, X., Malik, S., Verma, D. S., Yang, R., Zhao, B., Ding, S., Zhang, W., & Sharma, S. K. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01437a · Cited by 33

Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology

Menéndez, J. A., Cuyàs, E., Encinar, J. A., Steen, T. V., Verdura, S., Llop‐Hernández, À., López, J., Serrano‐Hervás, E., Osuna, S., Martín-Castillo, B., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13582 · Cited by 41

Nanomaterial-mediated modulation of the cGAS-STING signaling pathway for enhanced cancer immunotherapy

Wang, Y., Liu, Y., Zhang, J., Peng, Q., Wang, X., Xiao, X., & Shi, K. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.008 · Cited by 31

Seizing the fate of lymph nodes in immunotherapy: To preserve or not?

Xu, Z., Li, Z., Cao, L., Zhong, N., Liu, X.-H., Wang, G.-R., Xiao, Y., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216740 · Cited by 31

RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors

Ganesh, S., Kim, M. J., Lee, J., Feng, X., Ule, K., Mahan, A. L., Krishnan, H. S., Wang, Z., Anzahaee, M. Y., Singhal, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.035 · Cited by 31

IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside

Vahidi, S., Touchaei, A. Z., & Samadani, A. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112156 · Cited by 31

Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer

Wang, Y., Chen, Y., Ji, D., Huang, Y., Huang, W., Dong, X., Yao, D., & Wang, D. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02727-7 · Cited by 34

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

Moon, S., Jung, M., Go, S., Hong, J., Sohn, H. S., Kim, C., Kang, M., Lee, B. J., Kim, J.-W., Lim, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202410340 · Cited by 33

Genomic landscape of cancer in racially and ethnically diverse populations

Thomas, C. E., & Peters, U. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00796-w · Cited by 32

Photothermal Therapy: From Encouraging Lab Results to Lackluster Clinical Translation

Buiel, J., Robert, J., Mekhjian, D., Chauhan, D. S., & Banquy, X. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400347 · Cited by 31

NIR-II Engineered Exosome Nanotheranostic Probes for “Oriented Blasting” in Orthotopic Glioblastoma

Yu, D., Ding, Q., Xiang, C., Wang, D., Hu, L., Wang, J., Qian, K., Cheng, Z., & Li, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01541 · Cited by 32

Ferroptosis in immune cells: Implications for tumor immunity and cancer therapy

Gao, J., Zhang, X., Liu, Y., & Gu, X. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.06.007 · Cited by 34

T cells in cancer: mechanistic insights and therapeutic advances

Pu, J., Liu, T., Zhou, Y., Chen, M., Fu, X., Wan, Y., Wang, J., Chen, B., Sharma, A., Lukacs‐Kornek, V., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00807-w · Cited by 33

Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations

Shebbo, S., Alateyah, N., Yassin, E., Mahmoud, D. E. S., Tamimi, F., Anweigi, L. M., Elhissi, A. M. A., Abou-Saleh, H., Elrayess, M. A., & Agouni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626243 · Cited by 41

Lymph nodes fuel KLF2-dependent effector CD8+ T cell differentiation during chronic infection and checkpoint blockade

Tsui, C., Heyden, L., Wen, L., de Graça, C. G., Potemkin, N., Frolov, A., Rawlinson, D., Qin, L., Wimmer, V. C., Hadian-Jazi, M., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02276-7 · Cited by 37

Microbiota-induced T cell plasticity enables immune-mediated tumour control

Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 38

Thymic health and immunotherapy outcomes in patients with cancer

Bernatz, S., Prudente, V., Pai, S., Kjær, A., Federico, A. D., Rowan, A., Veeriah, S., Dyrskjøt, L., Nürnberg, L., Alessi, J. V., et al. (2026) · Nature · doi:10.1038/s41586-026-10243-x · Cited by 42

Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints

Kreileder, M., Barrett, I. P., Bendtsen, C., Brennan, D. J., & Kölch, W. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.001 · Cited by 31

The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities

Amôr, N. G., Santos, P. S. D. S., & Campanelli, A. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636544 · Cited by 32

Layer-by-Layer technique as a versatile tool for gene delivery applications

Linnik, D., Tarakanchikova, Y. V., Zyuzin, M. V., Lepik, K. V., Aerts, J. L., Sukhorukov, G. B., & Timin, A. S. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1879790 · Cited by 33

Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment

Ring, S. S., Cupovic, J., Onder, L., Lütge, M., Perez‐Shibayama, C., Gil‐Cruz, C., Scandella, E., Martin, A. D., Mörbe, U., Hartmann, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25057-w · Cited by 31

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells

Wang, H., Wang, L., Li, Y., Li, G., Zhang, X., Jiang, D., Zhang, Y.-T. Y., Liu, L., Chu, Y., & Xu, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02151-z · Cited by 31

Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures

de Mey, S., Dufait, I., & Ridder, M. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.761901 · Cited by 33

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Yu, X., Li, W., Young, K. H., & Li, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9111702 · Cited by 37

Review article: hepatitis B—current and emerging therapies

Yardeni, D., & Ghany, M. G. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16828 · Cited by 34

CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives

Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 34

Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy

Lan, T., Que, H., Luo, M., Zhao, X., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01550-8 · Cited by 31

Understanding of Antigen and Phenotypic Plasticity Molecules for the Purpose of Cancer Immunotherapy

Malviya, R., Singh, A. K., & Yadav, D. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003533955-4

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 148

Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer

Ali, S., Arshad, M., Summer, M., Zulfiqar, M., Noor, S., Nazakat, L., & Javed, M. A. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324896 · Cited by 10

T Lymphocyte–Based Cancer Immunotherapeutics

Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211